Vienna (Austria), December 15, 2010 -- Looking back at the year 2010, Hermann A.M. Mucke, Ph.D., H.M. Pharma Consultancy's owner and manager, gave the following statement today:

"In this exciting year that now draws to a close, H.M. Pharma Consultancy made some fundamental advances. Business developed satisfactory, rebounding impressively from its low point in 2009 when the global economic crisis fully hit and forced many of our customers to lie low for a time. Our customer structure as well as our digital presentation has diversified and globalized. In terms of strategic orientation we continued our emphasis on knowledge management and advanced open source intelligence in the life sciences."

"In January we relaunched our website and became active on Twitter, adding another facet to our extended web presence which we had already begun to expand with our blog (http://hmpharmacon.blogspot.com/) where most of our breaking news is now being presented. In December we started our discussion group on drug repurposing on the LinkedIn professional network. This builds on the good reception that our July 2010 market and technology report, "Drug Repositioning: Extracting Added Value from Prior R&D Investments" enjoyed. The group was an instant success, drawing 45 top-rate participants from the field within less than two weeks and spurning vivid discussions."

In 2011 H.M. Pharma Consultancy will continue on its path that has already made it a well-accepted international resource for life science consulting, knowledge management, and networking. Drug repurposing, which offers a viable alternative to new chemical entity development, is emerging as a new focus area."